Qiming Venture Partners and Multiple Portfolio Companies Named to Jazzyear's 2024-2025 China Tech Industry Investment Rankings
The list aims to recognize outstanding investment institutions, investors, and science and technology innovation enterprises that have made significant contributions to the development of China's tech industry.
Recently, Jazzyear released its 2024-2025 China Tech Industry Investment Rankings, an annual list recognizing outstanding investment institutions, investors, and technology companies that have made significant contributions to China's tech industry.
Qiming Venture Partners was named to both the AI Best Investment Institutions TOP30 and Healthcare Best Investment Institutions TOP30. Alex Zhou, Managing Partner at Qiming Venture Partners, was named to the AI Best Investors TOP20. Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation, was named to the Healthcare Best Investors TOP20. In addition, Qiming portfolio companies StepFun, Shengshu Technology, Infinigence AI, Tashi Zhihang, Galaxy Universal, Shenkepu Industrial, Bailinke, Jieti Medical, Shize Biotech, Ze'an Biopharmaceutical, and Lattice Power were selected for the Most Investment-Worthy Companies list.
Qiming Venture Partners
Named to
AI Best Investment Institutions TOP30
Healthcare Best Investment Institutions TOP30
Alex Zhou, Managing Partner at Qiming Venture Partners
Named to
AI Best Investors TOP20
Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation
Named to
Healthcare Best Investors TOP20
StepFun, Shengshu Technology, Infinigence AI
(AI and Big Data)
Tashi Zhihang, Galaxy Universal
(Embodied Artificial Intelligence)
Shenkepu Industrial
(Advanced Manufacturing)
Bailinke, Jieti Medical
Shize Biotech, Ze'an Biopharmaceutical
(Healthcare)
Lattice Power
(New Energy)
Named to
Most Investment-Worthy Companies
2024-2025 China Tech Industry Investment Rankings
The rankings evaluated institutions across multiple dimensions, including capital strength, brand influence, innovation capability, commercial viability, and external reputation, with weighted scoring to assess overall competitiveness.
Jazzyear noted that tech investment is undergoing a comprehensive recalibration and restructuring: hard tech is becoming the dominant investment direction, the full-stack transformation of AI is reshaping investment logic, and AI infrastructure, embodied intelligence, and AI agents are rapidly emerging as hot investment themes. International capital is also reassessing the value of China's tech industry, with sovereign wealth funds elevating China in their investment priorities and focusing on digital technology, advanced manufacturing, clean energy, and healthcare.
The role of GPs is being redefined. The traditional "capital provider" model has shifted toward "post-investment enabler" and is evolving further into "industrial ecosystem builder." The new investment logic demands that GPs not only identify the right projects with precision, but also participate deeply in company growth to ultimately create sustainable investment flywheels. These shifts indicate that Chinese tech investment is moving away from a reliance on "trends" and "information asymmetry" toward an empowerment-driven model that emphasizes "industrial depth" and "long-termism."
Source | Jazzyear
Past Highlights
Star Portfolio | Four Qiming Venture Partners Portfolio Companies Named to Cyzone 2024 Hard Tech Innovators 50 Qiming Honors | Duane Kuang, William Hu, and Alex Zhou Named to PEDaily 2025 TOP100 Investors Star Portfolio | Multiple Qiming Venture Partners Portfolio Companies Featured at World Robot Conference 2025
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, Qiming has focused on investing in early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming's portfolio companies have grown into the most influential companies in their respective sectors, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, among others.